Table 4.
Univariate and multivariate regression analyses between anti-Pg-LPS IgG levels and RA disease activity indices.
| Independent variable | Anti-Pg-LPS IgG | |||
|---|---|---|---|---|
| Dependent variables | Univariate model | Multivariate model a | ||
| ρ value | p value | Standardized β (95%cl) | p value | |
| DAS28-CRP | -0.277 | 0.009∗∗ | -0.226 (-0.448 : -0.003) | 0.047∗ |
| TJC | -0.218 | 0.043∗ | -0.160 (-0.378 : 0.060) | 0.151 |
| pVAS | -0.376 | <0.001∗∗ | -0.353 (-0.567 : -0.137) | 0.002∗∗ |
| eVAS | -0.315 | 0.003∗∗ | -0.271 (-0.488 : -0.053) | 0.016∗∗ |
| PainVAS | -0.433 | <0.001∗∗ | -0.408 (-0.614 : -0.202) | <0.001∗∗ |
| SDAI | -0.308 | 0.004∗∗ | -0.263 (-0.484 : -0.042) | 0.021∗ |
| CDAI | -0.309 | 0.004∗∗ | -0.266 (-0.486 : -0.045) | 0.019∗ |
DAS28: disease activity score with 28 joint counts; CRP: C-reactive protein; TJC: tender joint counts; pVAS (eVAS): patient's (evaluator's) visual analogue scale; painVAS: VAS for pain; SDAI: simplified disease activity index; CDAI: clinical disease activity index; ρ: Spearman's correlation coefficient; β: standardized regression coefficient; 95% CI: 95% confidence interval. Significant difference: ∗∗p < 0.01, ∗p < 0.05. aAdjusted for age, sex, smoking, and methotrexate treatment.